Biotech · Private company · Del Mar, CA, US
Virogenics, Inc.
Track this companyFree. Adds Virogenics, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials10 recruiting or active
Pipeline programs1From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline1
- CMS121Phase 1 · Alzheimer DiseaseClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials1
- Safety, Tolerability and Pharmacokinetics of CMS121, a Drug Candidate for Alzheimer's Disease, in Healthy SubjectsPHASE1 · COMPLETED · started May 1, 2022ClinicalTrials.gov NCT05318040 · fetched Nov 12, 2026
NIH awards5
- Long-term, non-clinical toxicology for advancing CMS121 to Phase 2 trials for ADFiscal year 2026 · $193.7KNIH RePORTER 3U01AG084549-03S1 · fetched Nov 12, 2026
- Long-term, non-clinical toxicology for advancing CMS121 to Phase 2 trials for ADFiscal year 2026 · $1.3MNIH RePORTER 5U01AG084549-03 · fetched Nov 12, 2026
- Long-term, non-clinical toxicology for advancing CMS121 to Phase 2 trials for ADFiscal year 2025 · $1.6MNIH RePORTER 5U01AG084549-02 · fetched Nov 12, 2026
- Paving the Way to Phase 2 Trials of CMS121 for Alzheimer's DiseaseFiscal year 2024 · $2.4MNIH RePORTER 1R44AG085775-01A1 · fetched Nov 12, 2026
- Long-term, non-clinical toxicology for advancing CMS121 to Phase 2 trials for ADFiscal year 2024 · $1.6MNIH RePORTER 1U01AG084549-01 · fetched Nov 12, 2026